Multiple sclerosis and demyelinating diseases

@inproceedings{Freedman2006MultipleSA,
  title={Multiple sclerosis and demyelinating diseases},
  author={Mark S. Freedman},
  year={2006}
}
Multiple Sclerosis Natural history: The London, Ontario database The Lyon database Genetic Aspects Pathology: Heterogeneity of pathology Gray vs. White matter disease-Proposed author: Bruce Trapp. 30 manuscript pages including tables and references 5 photos/diagrams Biology of MS: This section will discuss the current knowledge regarding the function of oligodendrocytes, their derivision from precursor cells, their properties (mostly from in vitro studies) and the potential for regeneration… Expand

References

SHOWING 1-10 OF 1,386 REFERENCES
Multiple Sclerosis: Current Pathophysiological Concepts
TLDR
This work reviews the evidence supporting the causative role of direct toxins, cell-mediated and humorally mediated immune mechanisms, and the concept of a “primary oligodendrogliopathy” in demyelination and axonal injury and suggests therapeutic implications and approaches suggested by putative pathophysiological mechanisms. Expand
Progress in deciphering the genetics of multiple sclerosis.
TLDR
Multiple sclerosis is a complex trait that is associated with the major histocompatibility complex, although the form of this association may not be as straightforward as previously thought. Expand
Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
TLDR
At a given time point of the disease, the patterns of demyelination were heterogeneous between patients, but were homogenous within multiple active lesions from the same patient, suggesting that MS may be a disease with heterogeneous pathogenetic mechanisms. Expand
Indirect evidence for early widespread gray matter involvement in relapsing–remitting multiple sclerosis
TLDR
The concept of MS, even at its earlier stages, as a WM disease might need to be reexamined because WBNAA loss greater than 40% x 2/3 = 27% cannot be explained in terms of WM pathology alone and must include widespread GM (neuronal) deficits. Expand
Pathogenesis of multiple sclerosis: The eyes only see what the mind is prepared to comprehend
TLDR
The article questions current concepts of MS lesion pathogenesis by identifying pathological changes that precede leukocyte infiltration and demyelination by proposing apoptotic oligodendrocyte death in a circumscribed and relatively small area (2–10mm in diameter) as the initial event in new lesion formation. Expand
New concepts in the immunopathogenesis of multiple sclerosis
TLDR
Recent advances in understanding of the pathogenesis of MS are summarized, and an outlook on how to capitalize on this knowledge to develop new therapeutic approaches is concluded. Expand
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance.
TLDR
Atrophy provides a sensitive measure of the neurodegenerative component of multiple sclerosis and should be measured in trials evaluating potential anti-inflammatory, remyelinating or neuroprotective therapies. Expand
The CD4–Th1 model for multiple sclerosis: a crucial re-appraisal
TLDR
Taken together, these issues prompt reconsideration of the use of pure CD4–Th1 models in favor of a view that MS is likely to be heterogeneous and might not be strictly autoimmune. Expand
Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy.
TLDR
The present data suggest that in vivo MRS indicates key pathologic features of demyelinating lesions in patients with diagnostically equivocal findings for multiple sclerosis. Expand
Imaging axonal damage in multiple sclerosis by means of MR spectroscopy
TLDR
It is argued for the early treatment of multiple sclerosis with agents directed not only against inflammation, but also towards axonal protection, and for the apparently primary role of axonal damage and loss in the pathogenesis of the disease should be given due importance. Expand
...
1
2
3
4
5
...